Device type · KXT
Enzyme Immunoassay, Digoxin
Last checked: Nov 19, 2026Source: openFDAMethods & limitations
Product code
KXT
Clinical Toxicology
Device class
Class II
FDA decisions since 2015
2
510(k), De Novo and PMA
Adverse event reports
3
Received Nov 1, 2025 to Nov 19, 2026
How FDA classifies it
- Device type
- Enzyme Immunoassay, Digoxin
- Product code
- KXT
- Device class
- Class II
- Review panel
- Clinical Toxicology
- Regulation
- 21 CFR 862.3320
- Specialty
- Laboratory Medicine & Pathology
- FDA record
- Classification database entry for KXT
Latest FDA decisions
Siemens Healthcare Diagnostics, Inc.
K193397 · Decided Jul 16, 2021 · 588 days after receipt
Device type: Enzyme Immunoassay, Digoxin (KXT) · Laboratory Medicine & Pathology
K153301 · Decided Apr 8, 2016 · 147 days after receipt
Device type: Enzyme Immunoassay, Digoxin (KXT) · Laboratory Medicine & Pathology
Reports received
3
Received Nov 1, 2025 to Nov 19, 2026
Malfunction reports
3
100% of reports
Injury reports
0
0.0% of reports
Death reports
0
0.0% of reports
Adverse event reports received per month
By the date FDA received each report, stacked by event type. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 0 | 0 | 0 | 0 |
| Jan 24 | 1 | 0 | 0 | 0 |
| Feb 24 | 0 | 0 | 0 | 0 |
| Mar 24 | 2 | 0 | 0 | 0 |
| Apr 24 | 0 | 0 | 0 | 0 |
| May 24 | 0 | 0 | 0 | 0 |
| Jun 24 | 1 | 0 | 0 | 0 |
| Jul 24 | 0 | 0 | 0 | 0 |
| Aug 24 | 0 | 0 | 0 | 0 |
| Sep 24 | 1 | 0 | 0 | 0 |
| Oct 24 | 1 | 0 | 0 | 0 |
| Nov 24 | 0 | 0 | 0 | 0 |
| Dec 24 | 1 | 0 | 0 | 0 |
| Jan 25 | 0 | 0 | 0 | 0 |
| Feb 25 | 0 | 0 | 0 | 0 |
| Mar 25 | 0 | 0 | 0 | 0 |
| Apr 25 | 0 | 0 | 0 | 0 |
| May 25 | 0 | 0 | 0 | 0 |
| Jun 25 | 0 | 0 | 0 | 0 |
| Jul 25 | 0 | 0 | 0 | 0 |
| Aug 25 | 0 | 0 | 0 | 0 |
| Sep 25 | 0 | 0 | 0 | 0 |
| Oct 25 | 0 | 0 | 0 | 0 |
| Nov 25 | 0 | 0 | 0 | 0 |
| Dec 25 | 0 | 0 | 0 | 0 |
| Jan 26 | 0 | 0 | 0 | 0 |
| Feb 26 | 0 | 0 | 0 | 0 |
| Mar 26 | 0 | 0 | 0 | 0 |
| Apr 26 | 1 | 0 | 0 | 0 |
| May 26 | 0 | 0 | 0 | 0 |
| Jun 26 | 0 | 0 | 0 | 0 |
| Jul 26 | 1 | 0 | 0 | 0 |
| Aug 26 | 0 | 0 | 0 | 0 |
| Sep 26 | 0 | 0 | 0 | 0 |
| Oct 26 | 1 | 0 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Manufacturers named most often
Last 12 months. Bigger sellers get more reports. This is not a ranking of safety.
Device problems as coded
Last 12 months. FDA's terms. A report can carry several.
- Incorrect, Inadequate or Imprecise Result or Readings2
- False Positive Result1
- High Test Results1
- Low Test Results1
Patient problems as coded
Last 12 months. FDA's terms. A report can carry several.
- No Clinical Signs, Symptoms or Conditions3
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Siemens Healthcare Diagnostics, Inc.
Z-2607-2017 · Started Mar 21, 2017 · Posted by FDA May 5, 2017
Reason given: The concentrations for Biotin listed in the Non-Interfering Substances section of the current Dimension and Dimension Vistat Instructions for Use (IFU) for Dimension TNI, Dimension Vista DIGXN, E2, FERR, PRL, and TSH have incorrect units, and incorrectly state the level at which biotin does not interfere.
Cause as FDA categorized it: Under Investigation by firm
Siemens Healthcare Diagnostics, Inc.
Z-1151-2013 · Started Feb 21, 2013 · Posted by FDA Apr 18, 2013
Reason given: Siemens has confirmed complaints of low QC and patient recovery with the Dimension Vista(R) LOCI(R) Digoxin(DIGXN) Flex(R) reagent cartridge when calibrating DIGXN with either Drug 4 Cal (KC460) lot 2KD052 or Drug 4 Cal (KC460A) lot 2KD053. Internal testing has shown an average 15% low bias in the therapeutic range of...
Cause as FDA categorized it: Process control
Abbott Diagnostic International, Ltd.
Z-0297-2009 · Started May 22, 2008 · Posted by FDA Nov 21, 2008
Reason given: AxSYM TDM/ Transplant Assay Disks 3D53-03 and higher do not contain the AxSYM Digoxin II Assay file. The instrument might require installation of the AxSYM Digoxin II assay file.
Cause as FDA categorized it: Software change control
Abbott Diagnostic International, Ltd.
Z-0064-2008 · Started Jul 20, 2007 · Posted by FDA Nov 3, 2007
Reason given: Incorrect Results -- Error codes 1062, 1063, 1113, and 1118 observed when running patient samples on the AxSYM Digoxin III assay, rather than a concentration, is reported for the patient sample.
Cause as FDA categorized it: Labeling design
Abbott Diagnostic International, Ltd.
Z-1202-2007 · Started Mar 30, 2007 · Posted by FDA Aug 29, 2007
Reason given: Customers are receiving error codes (1062, 1063, 1113, & 1118) when running patient samples on the AxSYM Digoxin III assay.
Cause as FDA categorized it: Other
Z-0736-2007 · Started Mar 16, 2007 · Posted by FDA Apr 13, 2007
Reason given: The lower detection limit (LDL) may be a higher value than stated in the labeling. Note: To resolve this issue, the Digoxin LDL claim has been revised to 0.3 ng/mL for all reagent lots.
Cause as FDA categorized it: Other
Z-0576-05 · Started Feb 23, 2005 · Posted by FDA Mar 8, 2005
Reason given: Variability in results on Patient and QC results of 20-25%, high and low.
Cause as FDA categorized it: Other
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.